Clinical study of Xihuang Capsule combined with albumin paclitaxel in treatment of advanced triple negative breast cancer
10.7501/j.issn.0253-2670.2020.24.022
- VernacularTitle: 西黄胶囊联合白蛋白紫杉醇治疗晚期三阴性乳腺癌临床研究
- Author:
Xiao-Yu ZHANG
1
Author Information
1. Cangzhou Central Hospital
- Publication Type:Journal Article
- Keywords:
Adverse reactions;
Albumin paclitaxel;
Breast cancer;
Tumor markers;
Xihuang Capsule
- From:
Chinese Traditional and Herbal Drugs
2020;51(24):6324-6327
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinical effect of Xihuang Capsule combined with albumin paclitaxel in the treatment of advanced triple negative breast cancer. Methods: A total of 80 patients with advanced triple negative breast cancer admitted to Cangzhou Central Hospital were selected as the study subjects. All patients were randomly divided into the control group and the treatment group, with 40 patients in each group. Patients in the control group were given albumin paclitaxel for a cycle of 21 d, and received continuous treatment for at least three cycles. The difference between the treatment group was given six capules of Xihuang Capsules twice a day for one course of treatment for 21 d based on the treatment of control group. The clinical effects of the two groups were compared and analyzed. The KPS and VAS scores of the two groups of patients were evaluated, and the tumor markers and the incidence of adverse reactions after taking the drug were recorded for statistical analysis. Results: After treatment, the objective remission rate (ORR) was 60.0% in the control group and 75.0% in the treatment group. The disease control rate (CBR) was 77.5% in the control group and 85.7% in the treatment group. The difference between the two groups was statistically significant (P < 0.05). After treatment, KPS score and VAS score in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, CA-153 and CEA levels of tumor markers in both groups were significantly lower than those before treatment (P < 0.05), while CA-153 and CEA levels in the treatment group were lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion: Xihuang Capsule combined with albumin paclitaxel has higher clinical efficacy and safety in patients with advanced triple negative breast cancer.
